S napshot N Achieving Operational Excellence N Other Initiatives for Fulfilling Our Social Responsiblities Annual Report 2014 _  Astellas Pharma Inc.  19 2013 2014 Sep. P  Included for a third consecutive year in the Dow Jones Sustainability Asia Pacific Index, one of the  world’s premier indexes for socially responsible investment (SRI) Aug. P  Initiatives to Contribute to Access to Health: Received the Minister of Health, Labour and Welfare  Award of the 11th Annual Merit Awards for Industry-Academia-Government Collaboration granted by  the Cabinet Office of Japan for initiatives in Neglected Tropical Diseases (NTDs) and integrated drug  discovery database iNTRODB Jul. P  Many employees participated in the community contribution volunteer activity, Astellas’ Changing  Tomorrow Day Apr. P  Initiatives to Contribute to Access to Health: Became a member of the Global Health Innovative  Technology Fund (GHIT Fund) Nov. P  Received an award for Pharmaceutical Company of the Year at the 9th SCRIP Awards hosted by  SCRIP Intelligence P  Received the IAUD Award in the packaging design category for the Bonoteo Tablets 50 mg container  at the IAUD Awards 2013, hosted by the International Association for Universal Design (IAUD) Mar. P  Selected by the Ministry of Economy, Trade and Industry for inclusion in the Diversity Management  Selection 100 P  Initiatives to Contribute to Access to Health: Awarded a GHIT Fund grant from the Pediatric Praziquantel  Consortium, in which Astellas participates 2013 2014 Apr. P  Established the position of Chief Medical Officer (CMO) Jul. P  Established a sales affiliate in Singapore Feb. P  Decided to conduct a stock split $_{R}$ A five-for-one stock split was conducted effective April 1, 2014 Sep. P  Signed an agreement with Accenture Japan Ltd. on business process outsourcing in regard to  certain Group-wide operations in Japan Dec. P  Signed an agreement with Mitsui Fudosan Co., Ltd. regarding comprehensive transfer of the  Company’s owned real estate $_{R}$ Transferred in March 2014 P  Production subsidiary Astellas Pharma Tech concluded a definitive agreement with Nichi-Iko on  succession of the Fuji Plant business $_{R}$ Succeeded in April 2014 P  Entered into an agreement with Taiho Pharmaceutical Co., Ltd. to transfer assets related to  fermentation research owned by the Company to Taiho